BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1363 related articles for article (PubMed ID: 29980462)

  • 21. Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and antimicrobial activities.
    Saltoglu N; Karali R; Yemisen M; Ozaras R; Balkan II; Mete B; Tabak F; Mert A; Hondur N; Ozturk R
    Int J Clin Pract; 2015 Jul; 69(7):766-70. PubMed ID: 25683907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors of community-onset urinary tract infections caused by plasmid-mediated AmpC β-lactamase-producing Enterobacteriaceae.
    Lee CH; Lee YT; Kung CH; Ku WW; Kuo SC; Chen TL; Fung CP
    J Microbiol Immunol Infect; 2015 Jun; 48(3):269-75. PubMed ID: 24239065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prevalence and predictors of extended spectrum B-lactamase urinary tract infections among emergency department patients: A retrospective chart review.
    Bou Chebl R; Assaf M; Kattouf N; Abou Arbid S; Haidar S; Geha M; Makki M; Tamim H; Abou Dagher G
    Am J Emerg Med; 2021 Nov; 49():304-309. PubMed ID: 34182275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prevalence and risk factors for extended-spectrum β-lactamase-producing Escherichia coli causing community-onset urinary tract infections in Colombia].
    Blanco VM; Maya JJ; Correa A; Perenguez M; Muñoz JS; Motoa G; Pallares CJ; Rosso F; Matta L; Celis Y; Garzon M; Villegas MV
    Enferm Infecc Microbiol Clin; 2016 Nov; 34(9):559-565. PubMed ID: 26774256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Third-Generation Cephalosporin Resistance and Associated Discordant Antibiotic Treatment in Emergency Department Febrile Urinary Tract Infections.
    Mark DG; Hung YY; Salim Z; Tarlton NJ; Torres E; Frazee BW
    Ann Emerg Med; 2021 Sep; 78(3):357-369. PubMed ID: 33781606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors for urinary tract infection caused by Enterobacteriaceae with extended-spectrum beta-lactamase resistance in patients admitted to internal medicine departments.
    Vardi M; Kochavi T; Denekamp Y; Bitterman H
    Isr Med Assoc J; 2012 Feb; 14(2):115-8. PubMed ID: 22693794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pediatric community acquired urinary tract infections due to extended-spectrum beta-lactamase versus non-extended-spectrum beta-lactamase producing bacteria.
    Alsubaie MA; Alsuheili AZ; Aljehani MN; Alothman AA; Alzahrani AS; Mohammedfadel HA; Alnajjar AA
    Pediatr Int; 2023; 65(1):e15620. PubMed ID: 37735838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of CTX-M-15 beta-lactamases in Enterobacteriaceae causing hospital- and community-acquired urinary tract infections as early as 2004, in Dar es Salaam, Tanzania.
    Manyahi J; Moyo SJ; Tellevik MG; Ndugulile F; Urassa W; Blomberg B; Langeland N
    BMC Infect Dis; 2017 Apr; 17(1):282. PubMed ID: 28415986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. International travel is a risk factor for extended-spectrum β-lactamase-producing Enterobacteriaceae acquisition in children: A case-case-control study in an urban U.S. hospital.
    Strysko JP; Mony V; Cleveland J; Siddiqui H; Homel P; Gagliardo C
    Travel Med Infect Dis; 2016; 14(6):568-571. PubMed ID: 27890813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Characterization of Extended-Spectrum β-Lactamase
    Shash RY; Elshimy AA; Soliman MY; Mosharafa AA
    Am J Trop Med Hyg; 2019 Mar; 100(3):522-528. PubMed ID: 30594263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging extended-spectrum β-lactamase-producing Klebsiella pneumoniae causing community-onset urinary tract infections: a case-control-control study.
    Boix-Palop L; Xercavins M; Badía C; Obradors M; Riera M; Freixas N; Pérez J; Rodríguez-Carballeira M; Garau J; Calbo E
    Int J Antimicrob Agents; 2017 Aug; 50(2):197-202. PubMed ID: 28552471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical profiles of patients colonized or infected with extended-spectrum beta-lactamase producing Enterobacteriaceae isolates: a 20 month retrospective study at a Belgian University Hospital.
    Schoevaerdts D; Bogaerts P; Grimmelprez A; de Saint-Hubert M; Delaere B; Jamart J; Swine C; Glupczynski Y
    BMC Infect Dis; 2011 Jan; 11():12. PubMed ID: 21226923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ESBL-producing enterobacteriaceae-related urinary tract infections in kidney transplant recipients: incidence and risk factors for recurrence.
    Pilmis B; Scemla A; Join-Lambert O; Mamzer MF; Lortholary O; Legendre C; Zahar JR
    Infect Dis (Lond); 2015; 47(10):714-8. PubMed ID: 26024285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for community-acquired urinary tract infections caused by ESBL-producing enterobacteriaceae--a case-control study in a low prevalence country.
    Søraas A; Sundsfjord A; Sandven I; Brunborg C; Jenum PA
    PLoS One; 2013; 8(7):e69581. PubMed ID: 23936052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy.
    Meier S; Weber R; Zbinden R; Ruef C; Hasse B
    Infection; 2011 Aug; 39(4):333-40. PubMed ID: 21706226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-carbapenem therapy of urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae.
    de La Blanchardière A; Dargère S; Guérin F; Daurel C; Saint-Lorant G; Verdon R; Cattoir V
    Med Mal Infect; 2015 May; 45(5):169-72. PubMed ID: 25845927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
    Calbo E; Romaní V; Xercavins M; Gómez L; Vidal CG; Quintana S; Vila J; Garau J
    J Antimicrob Chemother; 2006 Apr; 57(4):780-3. PubMed ID: 16492721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.
    Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL
    Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical patterns, epidemiology and risk factors of community-acquired urinary tract infection caused by extended-spectrum beta-lactamase producers: a prospective hospital case-control study.
    Almomani BA; Hayajneh WA; Ayoub AM; Ababneh MA; Al Momani MA
    Infection; 2018 Aug; 46(4):495-501. PubMed ID: 29748840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary tract infections caused by ESBL-producing Enterobacteriaceae in renal transplant recipients: A systematic review and meta-analysis.
    Alevizakos M; Nasioudis D; Mylonakis E
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28803446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 69.